Investigational ultra-long-acting insulin degludec reduces hypoglycaemia and improves long-term control
Links shared publicly online about this topic.
- 185total visits
Investigational ultra-long-acting insulin degludec reduces hypoglycaemia and improves long-term control
World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharmaceutical news and achievements.
View full resource at worldpharmanews.com
Most Recently Shared on June 28, 2011 at 8:41 pm By:
Investigational ultra-long-acting insulin degludec reduces hypoglycaemia and improves long-term control http://bit.ly/kEVRlH
Investigational Ultra-long-acting Insulin Degludec Reduces Hypoglycaemia And Improves Long-term Control In Patients With Type 1 And Type 2 Diabetes
medicalnewstoday.com — “Ultra-long acting insulin degludec, under development by Novo Nordisk, lowers blood glucose levels with significantly reduced rates of hypoglycaemia (low blood sugar) compared to insulin glargine,” View full resource at medicalnewstoday.com
Most Recently Shared on June 24, 2011 at 9:05 pm By:
Investigational Ultra-long-acting Insulin Degludec Reduces Hypoglycaemia And Improves Long-term Control In Patients Wi... http://mnt.to/3XF8
Advertisement
